@pippa-matt.bsky.socialA deeply problematic vaccine trial, funded by the US, is poised to withdraw lifesaving #HBV #vaccines in #Guinea-Bissau. This vaccine is a universal recommendation by @who.int… we know it is safe, effective & essential for eliminating viral hepatitis as a health threat.
www.hepb.org/news-and-eve...
@genesndiseases.bsky.socialUnderstanding #HBV-driven #LiverCancer could improve early detection.
This review highlights dysregulated #lncRNAs as regulators of viral replication and cancer, with potential as biomarkers and therapeutic targets.
#OpenAccess in #GenesAndDiseases: doi.org/10.1016/j.ge...
@danielhoffmann.eurosky.socialWould you enroll your baby in this study in a region with high prevalence of hepatitis B? Would you play Russian roulette with your baby?
www.theguardian.com/society/2026...
#hbv #hepatitisb #vaccines
@danielhoffmann.wsocial.euWould you enroll your baby in this study in a region with high prevalence of hepatitis B? Would you play Russian roulette with your baby?
www.theguardian.com/society/2026...
#hbv #hepatitisb #vaccines
@liversmdpi.bsky.social📢 New Article in #LiversMDPI
🧬 Aregawi et al. identified 6 HBV genotypes among 778 patients in a Canadian cohort.
🩺 Genotype C had the highest HBeAg positivity prevalence at 23.7%.
📖 Read More: www.mdpi.com/2673-4389/6/...
@amrgohar.bsky.social@genesndiseases.bsky.socialA newly uncovered brake on #HBV replication.
HOXD1 limits HBV transcription by suppressing #UFMylation, revealing a host defence pathway that regulates NF-κB signalling and may offer a new therapeutic target for chronic hepatitis B.
#GenesAndDiseases: doi.org/10.1016/j.ge...
@infdiseasesnow.bsky.social3➡️Une communication brève cherchant à déterminer la prévalence sérologique et moléculaire de l’infection par le VHD et à caractériser ses génotypes chez des personnes HBsAg-positives à Madagascar.
@eara.eu#GeneTherapy silences #HepatitisB virus in #mice 🧬
A #therapy developed in Italy (San Raffaele Telethon Institute for Gene Therapy) and the US (nChroma Bio) reduced #HBV activity in #mice and proved safe in #monkeys, paving the way for #ClinicalTrials.
Learn more: 🔗 www.eara.eu/news/gene-th...
@genesndiseases.bsky.socialTargeting RRM2 could tackle both #HCC and #HBV.
This study identifies HP28 and HP39 as RRM2 inhibitors that deplete dNTPs, suppress #tumor growth and HBV replication, and retain activity against sorafenib-resistant HCC.
#OpenAccess in #GenesAndDiseases: doi.org/10.1016/j.ge...
@cddpress.bsky.social“Hepatitis B virus protein X promotes survival and loss of hepatocyte identity in a differentiated human liver organoid system”
This physiologically relevant organoid model clarifies longstanding questions about the pathogenesis of #HBV-associated #HCC ⤵️
nature.com/articles/s41...
@pippa-matt.bsky.socialOur work with the #Mongolian community in #London 'MoLo' set out to raise awareness, develop pathways to care, collect data, and support lab research 🧪
#MedSky #LiverSky #PublicHealth #HBV #HIV #InclusionHealth
@crick.ac.uk @uclh.bsky.social @uclhresearch.bsky.social
www.crick.ac.uk/news/2026-09...
@pippa-matt.bsky.socialHepatitis B Companion talk the best way to open UK #HBV meeting…
tackling #stigma, providing #PeerSupport, developing #education, improving retention in care & #treatment access.
www.hepbcompanion.org
🧪
#LiverSky #HepSky
@worldhepalliance.bsky.social
@hepctrust.bsky.social
Supa Chantschool
@pippa-matt.bsky.socialCongratulations to Motswedi Anderson & team from @ahri-news.bsky.social, @crick.ac.uk, @uclnews.bsky.social for a prize at the #COLDA meeting (Conference on Liver Disease in #Africa) - we studied the interplay between #HBV, #HIV, #Alcohol & #Metabolic factors ( #MASLD) in #LiverDisease.
🧪 #MedSky
@pippa-matt.bsky.socialConference on #LiverDisease in #Africa ( #COLDA) meeting in #AddisAbaba, #Ethiopia. Inspiring enthusiasm from researchers & clinicians to drive advances for #elimination of viral #hepatitis and liver disease in Africa. @sdgactioncampaign.org @whowpro.bsky.social @crick.ac.uk #AfricaCDC #HBV #IDSky 🧪
@genesndiseases.bsky.socialHow can chronic #HBV be controlled despite T-cell exhaustion?
CXCR5+CD8+ T cells retain #antiviral effector and B-cell helper functions, correlate with lower viral markers, and may offer a new therapeutic strategy.
#OpenAccess in #GenesAndDiseases: doi.org/10.1016/j.ge...
@wimi-bio-tech.bsky.social#PekingUniversity researchers discovered PmCas12m—a naturally nuclease-dead miniature Cas nuclease—and engineered #xCas12m (581 aa), enabling #single-AAV packaging of xCas12m-CRISPRoff for durable in vivo HBV epigenetic silencing in mice. 🧬🤖 #Epigenetics #CRISPRoff #GeneTherapy #HBV
@pippa-matt.bsky.social#COLDA declaration: "Africa doesn't lack #vaccines, #diagnostics, #medicine, guidelines or expertise to tackle #hepatitis & #liver disease. The gap is #implementation. Call to #CDC to turn the #HBV tookit into a roadmap, service packages & national support." 🧪 @who.int @worldhepalliance.bsky.social
@esgvh.bsky.socialHonoured and proud that our Chair, Prof. @oana-sandulescu.bsky.social delivered a fantastic keynote at #ESCV2026 in Porto!
“Practical ART decision-making in HIV-HBV coinfection” - a timely reminder that HBV status matters in ART decisions.
#HIV #HBV
@escvirology.bsky.social
@escmid.bsky.social
@pippa-matt.bsky.socialReflecting on 5 years of progress, with data from multiple countries across #Africa being meticulously collated to represent people living with #HBV to understand and improve clinical management, outcomes, policy and funding.
#HEPSANET
#COLDA #hepatitis
www.hepsanet.org
🧪
